Ушбу иш иқтибос қилган ишлар

144 та иш

Иш: New approaches of chimeric antigen receptor (CAR)-immune cell-based therapy in gastric cancer; highlight CAR-T and CAR-NK

A view on drug resistance in cancer
Neil Vasan, José Baselga, David M. Hyman
Шарҳ мақола20197 иқтибос
ABI
The Proceedings of the National Academy of Sciences
Jos W. Richards
Мақола19155 иқтибос
ABI
Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention
Parisa Karimi, Farhad Islami, Sharmila Anandasabapathy +2
Шарҳ мақола20144 иқтибос
ABI
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
Diana Gumber, Leo D. Wang
Шарҳ мақола20224 иқтибос
ABI
Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
Bihui Cao, Manting Liu, Jingjun Huang +17
Мақола20213 иқтибос
ABI
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Changsong Qi, Jifang Gong, Jian Li +23
Мақола20223 иқтибос
ABI
Chimeric Antigen Receptor T Cell Therapy Targeting Epithelial Cell Adhesion Molecule in Gastric Cancer: Mechanisms of Tumor Resistance
Yanping Yang, Raymond H. Y. Louie, Janusz Puc +6
Мақола20233 иқтибос
ABI
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu +3
Шарҳ мақола20223 иқтибос
ABI
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain, Renier J. Brentjens, Isabelle Rivière
Шарҳ мақола20133 иқтибос
ABI
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Mohamed-Reda Benmebarek, Clara H. Karches, Bruno L. Cadilha +3
Шарҳ мақола20192 иқтибос
ABI
HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer
Xian Wu, Shucheng Huang
Мақола20192 иқтибос
ABI
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh +4
Шарҳ мақола20232 иқтибос
ABI
Development of NK cell-based cancer immunotherapies through receptor engineering
Audrey Page, Nicolas Chuvin, Jenny Valladeau‐Guilemond +1
Мақола20242 иқтибос
ABI
Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy
Bolong Tao, Ruoxin Du, Xiangmei Zhang +4
Мақола20232 иқтибос
ABI
Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance
Xiaolin Wang, Jiahui Zhang, Guozhen Cao +3
Шарҳ мақола20222 иқтибос
ABI
FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1/NRF2 signaling pathway
Yunjiang Zhou, Yaxin Chen, Yongwei Shi +6
Мақола20232 иқтибос
ABI
CircRNA: A new class of targets for gastric cancer drug resistance therapy
Ying Zheng, Zhe Li, Yao Wang +4
Шарҳ мақола20232 иқтибос
ABI
Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives
Jiahua Liu, Qihang Yuan, Hui Guo +3
Мақола20242 иқтибос
ABI
Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer
Ryul Kim, Minae An, Hyuk Lee +13
Мақола20212 иқтибос
ABI
Сарлавҳасиз
Бошқа2 иқтибос
ABI
Gastric cancer treatment: recent progress and future perspectives
Wen‐Long Guan, Ye He, Rui‐Hua Xu
Шарҳ мақола20232 иқтибос
ABI
CAR-NK cells for cancer immunotherapy: recent advances and future directions
Tianye Li, Mengke Niu, Weijiang Zhang +3
Мақола20242 иқтибос
ABI
Cancer immunoediting: from immunosurveillance to tumor escape
Gavin P. Dunn, Allen T. Bruce, Hiroaki Ikeda +2
Шарҳ мақола20022 иқтибос
ABI
Tumour heterogeneity and the evolution of polyclonal drug resistance
Rebecca A. Burrell, Charles Swanton
Шарҳ мақола20142 иқтибос
ABI
Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
Yanjing Song, Chuan Tong, Yao Wang +8
Мақола20172 иқтибос
ABI